Patients with advanced metastatic ovarian cancer and triple-negative breast cancer were treated with the BET inhibitor RO6870810 and the PD-L1 inhibitor atezolizumab following two alternative regimens, with or without an RO6870810 monotherapy run-in phase. This evidence concerns the gene DNER and triple-negative breast carcinoma.